Evaluation of MASLD Fibrosis, FIB-4 and APRI Score in MASLD Combined with T2DM and MACCEs Receiving SGLT2 Inhibitors Treatment

Overview

Journal Int J Gen Med

Publisher Dove Medical Press

Specialty General Medicine

Date 2024 Jun 10

PMID 38855422

Authors

Hua Liu

Yang-Min Hao

Sheng Jiang

Maiheliya Baihetiyaer

Cheng Li

Guo-Yao Sang

Zhiming Li

Guo-Li Du

Affiliations

Soon will be listed here.

Abstract

Purpose: This study aims to investigate the relationship between Sodium Glucose Co-transporter-2 inhibitors (SGLT2i) treatment and fibrosis in patients with Metabolic dysfunction-associated steatotic liver disease (MASLD) combined with Type 2 Diabetes Mellitus (T2DM) and Major Adverse Cardiovascular and Cerebrovascular Events (MACCEs).

Methods: A case-control study was conducted, involving 280 patients with MASLD combined with T2DM treated at the First Affiliated Hospital of Xinjiang Medical University from January 2014 to October 2023. Among these patients, 135 received SGLT2i treatment. The association between the Fibrosis-4 (FIB-4) index and the occurrence of MACCEs, as well as the association between the Aspartate Aminotransferase-to-Platelet Ratio Index (APRI) scores and MACCEs, were evaluated.

Results: The FIB-4 index and APRI scores were significantly lower in the SGLT2i treatment group compared to the non-SGLT2i group (1.59 vs 1.25, <0.001). SGLT2i treatment tended to reduce the occurrence of MACCEs compared to non-SGLT2i treatment (45.5% vs 38.5%, =0.28). All patients who developed MACCEs in the non-SGLT2i treatment group had higher FIB-4 index (1.83 vs 1.35, =0.003). Additionally, after SGLT2i treatment for a median duration of 22 months, patients showed significant reductions in blood glucose, APRI, and FIB-4 index.

Conclusion: SGLT2i treatment significantly reduces the occurrence of MACCEs and liver fibrosis in patients with MASLD combined with T2DM. The FIB-4 index may serve as a potential surrogate marker for predicting the occurrence of MACCEs.

References

Henson J, Simon T, Kaplan A, Osganian S, Masia R, Corey K . Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2020; 51(7):728-736. PMC: 7069774. DOI: 10.1111/apt.15660. View

Harrison S, Gawrieh S, Roberts K, Lisanti C, Schwope R, Cebe K . Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. J Hepatol. 2021; 75(2):284-291. DOI: 10.1016/j.jhep.2021.02.034. View

Arai T, Atsukawa M, Tsubota A, Mikami S, Ono H, Kawano T . Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data. Ther Adv Endocrinol Metab. 2021; 12:20420188211000243. PMC: 7989116. DOI: 10.1177/20420188211000243. View

Schonmann Y, Yeshua H, Bentov I, Zelber-Sagi S . Liver fibrosis marker is an independent predictor of cardiovascular morbidity and mortality in the general population. Dig Liver Dis. 2020; 53(1):79-85. DOI: 10.1016/j.dld.2020.10.014. View

Arslan F, Bongartz L, Ten Berg J, Jukema J, Appelman Y, Liem A . 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: comments from the Dutch ACS working group. Neth Heart J. 2018; 26(9):417-421. PMC: 6115313. DOI: 10.1007/s12471-018-1134-0. View

Anstee Q, Targher G, Day C . Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013; 10(6):330-44. DOI: 10.1038/nrgastro.2013.41. View

Becker L, Salameh W, Sferruzza A, Zhang K, ng Chen R, Malik R . Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States. Clin Gastroenterol Hepatol. 2009; 7(6):696-701. DOI: 10.1016/j.cgh.2009.01.010. View

Kjeldsen S, Farsang C, Sleigh P, Mancia G . 1999 WHO/ISH hypertension guidelines--highlights and esh update. J Hypertens. 2001; 19(12):2285-8. DOI: 10.1097/00004872-200112000-00026. View

Choi S, Kweon S, Lee Y, Ryu S, Nam H, Shin M . Association of liver fibrosis biomarkers with overall and CVD mortality in the Korean population: The Dong-gu study. PLoS One. 2022; 17(12):e0277729. PMC: 9747044. DOI: 10.1371/journal.pone.0277729. View

10.

Ferguson D, Finck B . Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol. 2021; 17(8):484-495. PMC: 8570106. DOI: 10.1038/s41574-021-00507-z. View

11.

Oikonomou D, Georgiopoulos G, Katsi V, Kourek C, Tsioufis C, Alexopoulou A . Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated?. Eur J Gastroenterol Hepatol. 2018; 30(9):979-985. DOI: 10.1097/MEG.0000000000001191. View

12.

Farkouh M, Verma S . Prevention of Heart Failure With SGLT-2 Inhibition: Insights From CVD-REAL. J Am Coll Cardiol. 2018; 71(22):2507-2510. DOI: 10.1016/j.jacc.2018.02.078. View

13.

Kasper P, Martin A, Lang S, Kutting F, Goeser T, Demir M . NAFLD and cardiovascular diseases: a clinical review. Clin Res Cardiol. 2020; 110(7):921-937. PMC: 8238775. DOI: 10.1007/s00392-020-01709-7. View

14.

Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G . A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010; 53(2):372-84. DOI: 10.1016/j.jhep.2010.04.008. View

15.

Doycheva I, Cui J, Nguyen P, Costa E, Hooker J, Hofflich H . Non-invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2015; 43(1):83-95. PMC: 4673036. DOI: 10.1111/apt.13405. View

16.

Zuo Z, Cui H, Wang M, Huang C, Wu J, Tao C . Diagnostic of FibroTouch and six serological models in assessing the degree of liver fibrosis among patients with chronic hepatic disease: A single-center retrospective study. PLoS One. 2022; 17(7):e0270512. PMC: 9249238. DOI: 10.1371/journal.pone.0270512. View

17.

Lamacchia O, Sorrentino M . Diabetes Mellitus, Arterial Stiffness and Cardiovascular Disease: Clinical Implications and the Influence of SGLT2i. Curr Vasc Pharmacol. 2020; 19(2):233-240. DOI: 10.2174/1570161118666200317150359. View

18.

Targher G, Lonardo A, Byrne C . Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol. 2017; 14(2):99-114. DOI: 10.1038/nrendo.2017.173. View

19.

Williamson R, Price J, Glancy S, Perry E, Nee L, Hayes P . Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2011; 34(5):1139-44. PMC: 3114489. DOI: 10.2337/dc10-2229. View

20.

Vilar-Gomez E, Chalasani N . Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol. 2017; 68(2):305-315. DOI: 10.1016/j.jhep.2017.11.013. View